Phase 2b trial of neflamapimod in dementia with Lewy bodies fails to replicate earlier promise
A phase 2b randomized trial found no benefit of neflamapimod on the primary CDR-SB outcome in dementia with Lewy bodies, ...
A phase 2b randomized trial found no benefit of neflamapimod on the primary CDR-SB outcome in dementia with Lewy bodies, ...
In a groundbreaking advancement in the treatment of Fabry disease, researchers have unveiled compelling results from a pivotal phase 3 ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.